menu
    • menu
    [{"orgOrder":0,"company":"Reistone Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1||Janus kinase 1 (JAK-1)","graph1":"Dermatology","graph2":"Phase III","graph3":"Reistone Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Reistone Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Reistone Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Reistone Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1||Janus kinase 1 (JAK-1)","graph1":"Dermatology","graph2":"Phase III","graph3":"Reistone Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Reistone Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Reistone Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Reistone Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1||Janus kinase 1 (JAK-1)","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Reistone Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Reistone Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Reistone Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Reistone Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1||Janus kinase 1 (JAK-1)","graph1":"Dermatology","graph2":"Phase III","graph3":"Reistone Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Reistone Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Reistone Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Reistone Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1||Janus kinase 1 (JAK-1)","graph1":"Immunology","graph2":"Phase III","graph3":"Reistone Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Reistone Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Reistone Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Reistone Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1||Janus kinase 1 (JAK-1)","graph1":"Dermatology","graph2":"Phase III","graph3":"Reistone Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Reistone Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Reistone Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Reistone Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1||Janus kinase 1 (JAK-1)","graph1":"Immunology","graph2":"Phase III","graph3":"Reistone Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Reistone Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Reistone Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Reistone Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1||Janus kinase 1 (JAK-1)","graph1":"Dermatology","graph2":"Phase III","graph3":"Reistone Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Reistone Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Reistone Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Reistone Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1||Janus kinase 1 (JAK-1)","graph1":"Immunology","graph2":"Phase II","graph3":"Reistone Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Reistone Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Reistone Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Reistone Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Phase III","graph3":"Reistone Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Reistone Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Reistone Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Reistone Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1","graph1":"Immunology","graph2":"Phase II","graph3":"Reistone Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Reistone Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Reistone Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Reistone Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"SHR1459","moa":"Tyrosine-protein kinase BTK","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Reistone Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Reistone Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Reistone Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Reistone Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"SHR1459","moa":"Tyrosine-protein kinase BTK","graph1":"Nephrology","graph2":"Phase II","graph3":"Reistone Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Reistone Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Reistone Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Reistone Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"RSS0393","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Reistone Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Reistone Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Reistone Biopharma \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Reistone Biopharma

    Menu

    Reistone Biopharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Reistone Biopharma

                            China arrow
                            AAPS
                            Not Confirmed

                            Reistone Biopharma

                            China arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RSS0393

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase II Trial of the Safety and Efficacy of RSS0309 Ointment in Adults With Atopic Dermatitis

                            Details : (RSS0393) is currently being evaluated in Phase II clinical studies for the treatment of Dermatitis, Atopic.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 05, 2025

                            Lead Product(s) : RSS0393

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Reistone Biopharma

                            China arrow
                            AAPS
                            Not Confirmed

                            Reistone Biopharma

                            China arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ivarmacitinib

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata

                            Details : SHR0302 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Alopecia Areata.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 22, 2022

                            Lead Product(s) : Ivarmacitinib

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Reistone Biopharma

                            China arrow
                            AAPS
                            Not Confirmed

                            Reistone Biopharma

                            China arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ivarmacitinib

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerativ...

                            Details : SHR0302 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Colitis, Ulcerative.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 06, 2022

                            Lead Product(s) : Ivarmacitinib

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Reistone Biopharma

                            China arrow
                            AAPS
                            Not Confirmed

                            Reistone Biopharma

                            China arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SHR1459

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluate the Efficacy and Safety of SHR1459 Tablets in Patients With Primary Membranous Nephropathy

                            Details : SHR1459 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Primary Membranous Nephropathy.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 29, 2021

                            Lead Product(s) : SHR1459

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Reistone Biopharma

                            China arrow
                            AAPS
                            Not Confirmed

                            Reistone Biopharma

                            China arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ivarmacitinib

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopi...

                            Details : SHR0302 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dermatitis, Atopic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 06, 2021

                            Lead Product(s) : Ivarmacitinib

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Reistone Biopharma

                            China arrow
                            AAPS
                            Not Confirmed

                            Reistone Biopharma

                            China arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ivarmacitinib

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Assess the Efficacy and Safety of SHR0302 Ointment in Adult Patients With Vitiligo

                            Details : SHR0302 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Vitiligo.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 01, 2021

                            Lead Product(s) : Ivarmacitinib

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Reistone Biopharma

                            China arrow
                            AAPS
                            Not Confirmed

                            Reistone Biopharma

                            China arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ivarmacitinib

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Patients With Mild-to-Moderate Atopic Dermatit...

                            Details : SHR0302 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Dermatitis, Atopic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 22, 2021

                            Lead Product(s) : Ivarmacitinib

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Reistone Biopharma

                            China arrow
                            AAPS
                            Not Confirmed

                            Reistone Biopharma

                            China arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ivarmacitinib

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Positive P2 Results for Reistone's JAK Inhibitor Demonstrate Significant Improvement in Patients with Moderate...

                            Details : SHR0302, an investigational selective Janus kinase type 1 (JAK1) inhibitor, met primary and key secondary endpoints in Reistone Biopharma's Phase 2 Clinical Study (AMBER2) for the treatment of patients with moderate to severe ulcerative colitis (UC).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 20, 2021

                            Lead Product(s) : Ivarmacitinib

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Reistone Biopharma

                            China arrow
                            AAPS
                            Not Confirmed

                            Reistone Biopharma

                            China arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SHR1459

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Open Label Study of the Effects of SHR1459 in NMOSDs Patients

                            Details : SHR1459 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Neuromyelitis Optica.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 17, 2020

                            Lead Product(s) : SHR1459

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Reistone Biopharma

                            China arrow
                            AAPS
                            Not Confirmed

                            Reistone Biopharma

                            China arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ivarmacitinib

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Reistone Biopharma Announces Positive Topline Results from Phase 2 Clinical Trial Evaluating SHR0302

                            Details : SHR0302 monotherapy achieved positive results on reaching primary endpoints with statistical significance, delivering significant improvements in skin clearance. Several late stage clinical studies are on-going in Ulcerative Colitis, Crohn's disease, etc...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 26, 2020

                            Lead Product(s) : Ivarmacitinib

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth